Working… Menu
Trial record 1 of 1 for:    A Phase III Multicenter, Randomized, Placebo-controlled, Double-blind Study of Atezolizumab
Previous Study | Return to List | Next Study

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03024996
Recruitment Status : Active, not recruiting
First Posted : January 19, 2017
Last Update Posted : April 9, 2021
Information provided by (Responsible Party):
Hoffmann-La Roche

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : January 18, 2022
Estimated Study Completion Date : February 24, 2024